Two new purpose-built facilities built for Almac Group in Northern Ireland to meet growing demand

By Liza Laws

- Last updated on GMT

© Almac Group's COO, Graeme McBurney
© Almac Group's COO, Graeme McBurney

Related tags facility Manufacturing Contract manufacturing CDMO

Almac Group, a global leader in CDMOs, announced today (March 6) that it has unveiled two new purpose-built facilities at its headquarters in Northern Ireland.

These expansions cater to the rising demand for commercial manufacturing, packaging, and peptide production, bolstering the operations of its business units, Almac Pharma Services and Almac Sciences.

The first facility, spanning 32,000 square feet, is a custom-built high-volume plant for Almac Pharma Services, significantly amplifying the capacity for commercial manufacturing and packaging of sachet drug product presentations. Equipped with additional manufacturing suites and automated packaging technologies, it also enhances the company's Quality Control (QC) Laboratory Testing capacity.

The second project encompasses a 28,000-square-foot Good Manufacturing Practice (GMP) facility, doubling the peptide Active Pharmaceutical Ingredient (API) manufacturing capacity for Almac Sciences. This expansion augments synthesis, purification, and isolation capabilities, aligning with the anticipated demand for clinical development and commercial products.

These expansions mark a milestone in Almac's ongoing global investment program, which has surpassed £400m / $500m since its inception in June 2022. Previous initiatives under this program include the establishment of a Centre of Excellence for Commercial Drug Product Partnership, a CDx Development, Manufacturing, and Commercial center, and a drug substance GMP facility.

Graeme McBurney, chief operating officer of Almac Group, said he was proud of the company's continued growth, emphasizing its commitment to delivering excellence to clients and patients worldwide.

Pride in company's continued growth

He said: “Our new peptide API manufacturing facility will significantly grow our portfolio of client APIs and is the latest stage of a wider development and manufacturing expansion initiative for Almac Sciences.”

McBurney highlighted Almac Pharma Services' efforts to enhance its large-scale commercial manufacturing and packaging capabilities, aligning with the increasing demand for tailored solutions to support clients' market growth needs. He emphasized the company's dedication to innovation and expansion, driven by a commitment to reinvesting profits back into the business.

With over 55 years of experience, Almac Group remains dedicated to advancing human health through continuous innovation and expansion. As a privately owned and independent company, it strives to meet the evolving needs of its clients and uphold its reputation as a trusted CDMO partner for the world's leading biopharma companies.

This news comes hot on the heels of last month (February)'s big news that saw Almac Pharma Services, a member of the Almac Group, receive a renewal of The Health Products Regulatory Authority (HPRA) Certificate of GMP Compliance for the company’s European facility.

The achievement comes following an in-depth, on-site five-day audit conducted by an HPRA inspector from November 6-10 last year (2023).  The certification applies to all labeling, and secondary packaging including specialist ultra-low temperature processing, analytical, and distribution activities performed at the company’s Dundalk, Ireland facility. 

Related news

Show more

Related products

show more

Ultra Low Temperature Packaging solutions

Ultra Low Temperature Packaging solutions

Content provided by Almac Group | 12-Feb-2024 | Case Study

Advanced Therapy Medicinal Products (ATMPs) offer ground-breaking opportunities for treating injuries and disease, in particular for cases of severe, untreatable...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Related suppliers

Follow us


View more